This allogeneic CAR-T product targeting Mucin 1 (MUC1) cell surface associated C-Terminal antigen utilises a Cas-CLOVER gene editing system to knockout TCR and MHC class 1 proteins, and is being tested in a phase I trial of advanced/metastatic epithelial-derived tumours including RCC [104,105]. Here, MUC1 is linked to neoplasm.